Advanced in Retrograde Ejaculation

Nianzeng Z. Xing

Chinese Academy Of Medical Sciences And Peking Union Medical College, 
Beijing, CN 
Advanced in Retrograde Ejaculation
Chinese Academy Of Medical Sciences And Peking Union Medical College, 
Beijing, CN 
OverviewLocationsClinical Research

Overview

Nianzeng Xing practices in Beijing, China. Xing is rated as an Advanced expert by MediFind in the treatment of Retrograde Ejaculation. Their top areas of expertise are Bladder Cancer, Prostate Cancer, Renal Cell Carcinoma (RCC), Nephrectomy, and Cystectomy.

Their clinical research consists of co-authoring 168 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of Retrograde Ejaculation.

Locations

Chinese Academy Of Medical Sciences And Peking Union Medical College, Beijing, 100000, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 31, 2024
Intervention Type: Drug
Study Drug: Fuzuloparib+Abiraterone Acetate+Prednisone
Study Phase: Phase 3

168 Total Publications

Phenotypic age acceleration as a novel predictor of benign prostatic hyperplasia: a prospective cohort study.
Phenotypic age acceleration as a novel predictor of benign prostatic hyperplasia: a prospective cohort study.
Journal: GeroScience
Published: May 19, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Xing's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 16 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile